Biologic Agents to Promote Periodontal Regeneration and Bone Augmentation

Area of Science:

• Periodontology
• Regenerative Medicine
• Biomaterials Science

Background:

• Periodontal regeneration, preferred over repair, involves excluding epithelial tissues to allow regeneration of cementum, bone, and connective tissue.
• Biologic materials are increasingly used as adjuncts to enhance wound healing and promote periodontal regeneration.

Purpose of the Study:

• To review biologic agents investigated for their potential to aid periodontal regeneration.
• To assess the efficacy and clinical applicability of various biologic factors in promoting hard- and soft-tissue regeneration in periodontal defects.

Main Methods:

• A literature review was conducted using MeSH terms: guided tissue regeneration, intercellular signaling peptides and proteins, and biologic factors.
• The review focused on agents including enamel matrix derivative (EMD), platelet-derived growth factor (PDGF), platelet-rich plasma, bone morphogenetic proteins (BMPs), fibroblast growth factor (FGF), and parathyroid hormone (PTH).

Main Results:

• Several biologic agents, including EMD, PDGF, BMPs, FGF, and PTH, have demonstrated potential in promoting hard- or soft-tissue regeneration.
• Enamel matrix derivative (EMD) and platelet-derived growth factor (PDGF) are FDA-approved for periodontal regeneration.
• Bone morphogenetic protein-2 (BMP-2) is approved for bone augmentation, while FGF and PTH lack FDA approval for periodontal applications.

Conclusions:

• No single biologic agent is universally suitable for all periodontal regeneration cases.
• Clinical decision-making requires careful evaluation of the specific clinical situation to determine the optimal biologic agent.
• Current FDA-approved agents for periodontal regeneration are limited to EMD and PDGF, with BMP-2 approved for bone augmentation.